You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

  • Technology appraisal guidance
  • Reference number: TA195
  • Published:  25 August 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer/sponsor

  • Abbott

  • Bristol-Myers Squibb

  • Roche

  • Schering-Plough (confidential information, including appendix 3, removed)

  • Wyeth


This page was last updated: 24 June 2010

Back to top